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Parathyroid hormone-related protein detection and interaction with
NO and cyclic AMP in the renovascular system. The presence of
parathyroid hormone-related protein (PTHrP) in human kidney vascula-
ture and the signal transduction pathways stimulated during PTHrP-
induced vasodilation of the rabbit kidney were investigated. Immunostain-
ing of human kidney revealed the abundant presence of PTHrP in media
and intima of all microvessels as well as in macula densa. In isolated
perfused rabbit kidney preconstricted with noradrenaline, i0 M Rp-
cAMPS, a direct inhibitor of protein kinase A, produced comparable
inhibition of 2.5 X i0 M forskolin- and i0— M PTHrP-induced
vasorelaxations. Renal vasorelaxation and renal microvessel adenylyl
cyclase stimulation underwent comparable desensitization following expo-
sure to PTHrP. Nitric oxide (NO)-synthase inhibition by L-NAME (10—a
M), NO scavenging by an imidazolineoxyl N-oxide (10 M) and guanylyl
cyclase inhibition by methylene blue (I0- M) decreased PTHrP-induced
vasorelaxation by 27 to 53%, abolished bradykinin-induced vasorelaxation
and did not affect forskolin-induced vasorelaxation. The effects of Rp-
cAMPS and L-NAME were not additive on PTHrP-induced vasorelax-
ation. Damaging endothelium by treating the kidney with either anti-
factor Vill-related antibody and complement, gossypol or detergent, did
not affect PTHrP- or forskolin-induced vasorelaxations but reduced
bradykinin-induced vasorelaxation by 53 to 92%. Conversely, endothelial
damage did not alter the inhibitoiy action of L-NAME on PTHrP-induced
vasorelaxation. In conclusion, PTHrP is present throughout the human
renovascular tree and juxtaglomerular apparatus. Activation of both
adenylyl cyclase/protein kinase A and NO-synthase/guanylyl cyclase path-
ways are directly linked to the renodilatory action of PTHrP in a way that
does not require an intact endothelium in the isolated rabbit kidney.
Over the years much attention has been paid to the role of the
renin-angiotensin system [1], endothelins [2], atrial natriuretic
peptides [3] and their interactions with the nitric oxide-synthase
pathways [4, 5] in the control of intrarenal hemodynamics. It is
clear, however, that other factors or homeostatic systems contrib-
ute to the control of renovascular hemodynamics. Parathyroid
hormone (PTH) is an additional factor which, besides its classical
role in mineral metabolism, has been observed to possess cardio-
vascular properties [6] and to be capable of modulating renal
vascular tone. PTH is a renal vasodilator [7] and renal arterioles
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have been shown to bind PTH with high affinity [8]. PTH also
stimulates arteriolar adenylyl cyclase [7] and the release of renin
[9, 10]. Despite these observations, the existence of a clear role for
PTH in renovascular homeostasis remains unlikely, for there is no
evidence that PTH is produced within the kidney, and it is unclear
how PTH secreted by the parathyroid glands could play a mean-
ingful role in regulation of arterial tone in the kidney.
PTH-related protein (PTHrP) was described in 1987 [reviewed
in 11, 12]. PTHrP is derived from a gene that is distinct from the
PTH gene yet shares striking amino acid and nucleotide homology
in the amino-terminal/S '-coding region with PTH. Amino-termi-
nal PTHrP secretoly species have been shown to bind to and act
through a common PTH/PTHrP receptor that is coupled to both
the adenylyl cyclase/protein kinase A and to protein kinase
C/cytosolic calcium signaling pathways in bone and renal tubules.
PTHrP has been shown to have a broad range of effects on cellular
proliferation and differentiation, on organ development and on
transepithelial calcium transport. In almost every instance, these
roles are paracrine or autocrine. The vascular biology of PTHrP is
currently one of the most active areas of investigation in the
PTHrP field. PTHrP has been shown to be a potent relaxant in
every type of smooth muscle including gastrointestinal [13, 14],
bladder [15], uterine [16], and, importantly in the current context,
aortic [17], coronary [18] and renal arterial [19] smooth muscle.
We have previously demonstrated that PTHrP causes dilation of
the renal arterial tree in intact rabbit and rat kidneys [7, 20]. These
actions are also observed in the in situ hydronephrotic model as
well. Studies in this latter model demonstrate that PTHrP dilates
the preglomerular vessels without affecting the efferent arteriole,
and that after inhibition of angiotensin converting enzyme PTHrP
dilates both pre- and post-glomerular arterioles [21]. A direct
stimulatory effect on renin release has also been shown [22].
These findings, together with the observations that PTHrP is
produced locally within every type of smooth muscle examined so
far (aortic, carotid, uterine, bladder, gastric), suggest that PTHrP
is likely to serve in a paracrine/autocrine fashion within the
renovascular tree and may play a physiologic role in the moment-
to-moment regulation of renovascular tone.
Evidence that PTH stimulates cAMP production in extrarenal
[23—28] as well as intrarenal [29, 30] vascular smooth muscle cells
has accumulated. Thus a role for cAMP as a second messenger for
the effect of PTHrP in vascular smooth muscle cells appears
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plausible. Indeed, PTHrP(1-34) increases cAMP production in rat
aortic smooth muscle cells [31, 32]. In rat aortic spiral strip
preparations, a direct cause-and-effect relationship between
cAMP production and the decrease of isometric tension by
PTHrP has been demonstrated [33]. On the other hand,
PTHrP(1-34) did not alter tissue cAMP level in the rabbit renal
arteries [19]. In isolated renal arterioles, PTHrP has been shown
to stimulate adenylyl cyclase activity with an EC50 value in the
nanomolar range [291. However, a direct cause-and-effect rela-
tionship between adenylyl cyclase stimulation and renal vasodila-
tion in response to PTHrP has not yet been demonstrated.
While the evidence linking cAMP to PTHrP-mediated renovas-
cular relaxation is reasonably secure, the question as to whether
the vasodilatory action of PTHrP involves endothelium-derived
nitric oxide (NO) signaling pathway, surprisingly has received less
attention. The relaxant effect of PTH in isolated rat aorta and
mesenteric vasculature does not require an intact endothelium
and appears to result from a direct effect on the vessel medial
layer [26]. On the other hand, in porcine coronary arteries,
removal of endothelial cells or pretreatment with nitro-L-argi-
nine, a NO-synthase inhibitor, impaired, although to a small
extent, PTH-induced relaxations [34]. In the isolated rabbit kidney
we have previously shown that the inhibition of NO-synthase by
L-NAME markedly reduced the PTHrP-induced relaxation [20].
In this latter study, the question as to whether the renal vascular
relaxation induced by PTHrP requires an intact endothelium was
not explored.
The current studies have two specific goals. First, to demon-
strate that PTHrP has the potential for playing a local physiologic
role, we wanted to determine whether PTHrP, which is known to
be produced in other vascular smooth muscle beds, is actually
produced within the intrarenal arterial tree. For these studies, we
chose to examine the normal human kidney, since we have
previously described the distribution of PTHrP in the rodent
kidney [35]. In that prior study, we examined neither the vascular
tree nor the macula densa for expression of PTHrP. The present
study also attempted to explore the role of the adenylyl cyclase!
protein kinase A and the endothelium/NO!guanylyl cyclase path-
ways in the renovasodilatory response to PTHrP and to determine
the interaction between these signal transduction systems. For
these studies we used the rabbit kidney.
Methods
Sources and preparations of drugs
The following synthetic peptides were obtained from Bachem
Feinchemikalien, AG (Bubbendorf, Switzerland): rat (r)PTH(1-34),
human (h)PTH(1-84) and hPTHrP(1-34). Adenosine 5'-triphos-
phate (ATP), guanosine 5'-triphosphate (GTP), creatine kinase and
creatine phosphate were obtained from Boehringcr (Mannheim,
Germany). Collagcnasc (clostridiopeptidase A from Clostridium
histolyticum) type I, noradrenaline (Nad), bradykinin (Bk), forskolin
(Fsk, from Coleus forskohlii), methylene blue (MB), N"'-nitro-L-
arginine methyl ester (L-NAME), L-arginine-HC1 (L-Arg), N6,2'-O-
dibutyryladenosine 3'5 '-cyclic monophosphate (dibutyryl-cAMP),
gossypol, 3-[(3-cholamidopropyl)-dimethylammonioj-1-propane-sul-
fonate (CHAPS), rabbit anti-human factor VIlI-related antigen
(F8rAg-ab) and guinea pig complement were from Sigma Chem-
ical Co. (St. Louis, MO, USA). 2-(4-carboxyphenyl)-4,4,5,5-tetram-
ethylimidazoline-1-oxyl-3-oxide (carhoxy-PTIO) was obtained from
Affiniti Research Products (Nottingham, UK). Kits of cAMP
binding protein assay were obtained from Amersham (Chicago,
IL, USA). (Rp)-adenosine cyclic 3',5'-phosphorothioate, [(Rp)-
cAMPS] were obtained from Calbiochem (La Jolla, CA, USA).
Immunohistological studies
For these studies, we elected to use normal human kidney, since
we have previously described the immunohistological staining
pattern in the rat kidney [36]. The results shown are from one
kidney but are representative of sections obtained from multiple
human kidneys. Healthy kidney was obtained from the unaffected
upper or lower poles of surgical specimens resected from patients
with hypernephroma [36], with the exception that immunoperox-
idase-labeled second antisera were employed in place of fluores-
cence-labeled antisera. For immunodetection of PTHrP, sections
were deparaffined and stained as described previously [361 using
immunoaffinity-purified rabbit antisera that recognize both
PTHrP(1-36) and PTHrP(37-74) as well as intact full-length
PTHrP(1 -74). Avidin-biotin complex immunoperoxidase was used
for detection. Two types of control were used, and included
staining in the absence of primary antibody, and staining in the
presence of primary antibody which had been pre-incubated with
PTHrP(1-36) or PTHrP(37-74) as appropriate [35, 36]. Previous
studies have shown that the region-specific PTHrP antisera used
in the present study are highly specific and do not cross-react with
PTH(1-84) or PTH(1-34) [37, 38].
Isolation and perfusion of rabbit kidney
Male and female New Zealand rabbits (2 to 2.2 kg) were
anaesthetized with tiletamine-zolazepam (Zoletil® 75 mg/kg i.m.;
Reading Laboratories, Paris, France). The left renal artery was
catheterized in situ with a dual-lumen 18G catheter (Sherwood
Medical, Tullamore, Republic of Ireland) allowing both the
perfusion of the kidney and the recording of perfusion pressure.
The left kidney was then removed from the animal and the
perfusion was pursued in vitro exactly as described before [20].
The perfusion medium was a Krebs-bicarbonate solution, pH 7.4
containing 30 g/liter modified gelatine as an oncotic agent, and (in
iO M): Na (150), K (5) Mg24 (1.5), Ca2 (1.5), lactate (30),
glucose (11) and NaHCO3 (24). The perfusion flow was adjusted to
4 ml/min/g of contralateral kidney, representing an overall mean
flow of 36.1 0.6 mI/mm (N = 66), in accordance with the
physiological renal blood flow measured in anaesthetized rabbits
[39], and was kept constant throughout the experiments. All
perfusions were performed in the presence of iO M indometh-
acm to rule out the involvement of vasoactive prostaglandins with
agonist-induced relaxations. As the isolated kidney has little if any
vasoconstrictor tone under basal resting conditions, vascular tone
was raised after an equilibration period, with Nad as indicated
below. All agonist or drug concentrations are given as final
concentrations in the perfusate.
NO-synthase-, protein kinase A - and endothelium-dependence of
PTHrP-induced vasorelaxation in the isolated rabbit kidney
These experiments were performed in kidney preparations
perfused in a closed recirculating circuit by recovering the effluent
flowing from the left renal vein directly into a recirculating
reservoir. The drugs and dilatory agonists were dissolved in small
volumes of perfusate (10 to 100 j.LJ) and directly added to the
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Experftnental groups ] Protocols 1
F— Equilibration Continuous infusion of 75 nmol/min of Nad
1) Control (3)
2) Control (4)
3) NOS inhibition (5)
4) NOS inhibition (5)
5) PKA inhibition (4)
6) PKA and NOS inhibition (3)
7) sGC inhibition (4)
8) NO scavenging (4)
9) Endothelium damage (5)
10) Endothelium damage (4)
11) Endothelium damage (6)
12) Endothelium damage
and NOS inhibition (6)
Time, minutes
130
Fig. 1. Diagram illustrating the timing of dmg injections in the 12 experimental groups perj'bnned to study the role of cAMP/protein kinase A (PKA),
NO/NO-synthase (NOS), soluble guanylyl cyclase (sGC), and endothelium, as signaling pathways of PTHrP-induced vasorelaxation in the isolated rabbit
kidney. The number of kidney preparations performed in each experimental group is indicated in parentheses. Experiments were performed in a closed
circuit by recovering the effluent flowing from renal vein into a recirculating reservoir. Drugs and dilatory agonists where added to the recirculating
perfusate, except for F8rAg-ab + cpmt and CHAPS treatments, during which the effluent was discarded. These latter compounds have been injected
at low flow in close proximity of the renal artery over the 10 first minutes and between minutes 8 and 9, respectively. The final concentrations of the
drugs are indicated in the text and figures.
recirculating perfusion circuit. The recirculating perfusate volume
was 72 ml. After a 50-minute equilibration period, kidney prepa-
rations were preconstrieted with a continuous infusion of Nad in
the recirculating circuit. A rate of 75 nmol/min was necessary to
obtain a sustained preconstriction and caused an increase in mean
renal perfusion pressure from about 40 mm Hg to values of 200
mm Hg. The relaxation rates induced successively by 10
hPTHrP(1-34), 2 X 10 6 M Bk or 10 M Ach, and 2.5 X io— M
Fsk, were studied under basal conditions or after administration
of the pharmacological tools used to inhibit various signaling
pathways or to damage endothelium. For clarity, the protocols
used and the number of kidney preparations performed in each of
the 12 independent experimental groups are depicted in Figure 1.
Desensitization of PTJ-frP-induced vasorelaxation in the isolated
perfused rabbit kidney
The recirculating closed circuit design does not allow accurate
control of the duration of exposure to the peptides. Therefore, for
desensitization experiments, the kidney preparations were per-
fused in a single-pass open circuit system. After an initial equili-
brating period of 50 minutes, the preconstricted state was induced
as above by iO— M Nad added to the perfusate. PTHrP(1-34) was
directly infused into the renal artery catheter, in close proximity to
the kidney, over periods of 1 or five minutes to yield a concen-
tration of 10_Il or 5 >< 10 M in the perfusate. After a
peptide-free interval of 10 minutes, rechallenge with 5 X 10_8 M
PTHrP was performed over a period of one minute.
Renal microvessel adenylyl cyclase desensitization
Rabbit renal microvessels were prepared in three successive
steps as described previously [29, 40] including the collagenase
digestion of renal interstitial tissue and dispersion of the renal
cortex into tubules, glomeruli and microvessels, the removal of all
glomeruli and a portion of the tubules by sieving the dissociated
cortical suspension through 125 and 70 m sieves, and the
centrifugation of the crude microvessels thus obtained on hyper-
tonic three-step sucrose gradients to achieve separation between
remaining tubules and the microvessels. Based on morphological,
biochemical, physiological and pharmacological criteria, this mi-
crovessel fraction is pure and is distinct from the tubules [8, 29,
40].
For desensitization experiments, microvessels obtained from 4
to 12 kidneys in bicarbonate-Ringer buffer, pH 7.4, containing (in
10 3M): NaCI (101) KC1 (7); CaC12 (1.5); MgSO4 (1.2); NaH2PO4
(1.2); NaHCO3 (17.5); sucrose (34) and glucose (11) were exposed
under continuous stirring and bubbling with 95% 02—5% CO2 to
PTH, PTHrP and agonists, for 10 minutes at 37°C. Control
treatments were performed under identical conditions, except
that buffer with no agonist was used. The treatment suspensions
were then cooled and washed twice with fresh buffer and naive,
T T
PTHrP Bk Fsk
0 10 50 60 70 80 90 100 110 120
1594 Massfelder et al: PTH-related protein in renal vasculature
Fig. 2. Immunohistological localization of PTHrP in human kidney vasculature. Staining was performed with affinity-purified, region-specific antibodies.
Kidney sections shown represent staining with an anti-PTHrP(37-74) antibody. A similar pattern was observed with addition of an anti-PTHrP(1-36)
antibody (not shown). (A to D) Arterioles near the glomerulus (x600). (E) Macula densa in contact with longitudinally cut arteriolar media near the
glomerulus (X600). (F) Interlobular artery branching into an arteriole near a glomerulus (x600). (G and H) Larger vessels, possibly upstream the
interlobular artery (X600). (L) Kidney section stained with anti-PTHrP(37-74) antibody preincubated with i0 M PTHrP(37-74) (X400).
control or agonist-treated microvessel homogenates containing 4
j.tg protein, were incubated at 30°C for 30 minutes in a total
volume of 200 .tl for adenylyl cyclase measurement, as described
previously [29].
Expression of the results and statistical analysis
Vasoactive responses to the drugs were expressed as maximal
percent change of the Nad-induced constriction. Adenylyl cyclase
activity was expressed as pmoles cAMP produced/mm/mg protein.
All data were represented as mean SEM. Analysis of variance
and Duncan's multiple range test were used to test for statistical
significance between the various experimental conditions. In all
cases, the significance level was set to P < 0.05.
Results
Immunohistological localization of PTHrP in the human kidney
As can be seen in Figure 2, PTHrP was detected in multiple
sites within the human kidney using the PTHrP (37-74) antiserum.
Similar results were observed using the PTHrP(1-36) antiserum.
These sites correspond well with the localization described previ-
ously in the rat kidney [36] and include the proximal and distal
tubules, the collecting duct, and the visceral and parietal epithelial
cells within the glomerulus (Fig. 2A—F). As in the rat, no PTHrP
was observed in mesangial cells. Importantly in the current
context, PTHrP was identified throughout the renal arterial tree,
from the arcuate (Fig. 2H) and interlobular arteries (Fig 2 F, G)
through the afferent and efferent arterioles (Fig. 2A—F). In the
vascular system, PTHrP was observed both in the smooth muscle
of the media as well as in the endothelium (Fig. 2 A—C, G, H). As
can be seen in Figure 2E, staining was particularly apparent in the
macula densa in contact with the adjacent arterial wall. PTHrP
staining was specific in that: (1) preincubation of the primary
antiserum with PTHrP as described in the Methods section
abolished the staining (Fig. 2L); and (2) elimination of the
primary antiserum also led to absence of staining (not shown).
Protein kinase A- and adenylyl cyclase-dependence of PTHrP-
induced vasorelaxation in the rabbit isolated kidney
A continuous infusion of 75 nmol/min of Nad into the recircu-
lating perfusate was necessary to obtain a stable and sustained
preconstriction over a period of 80 minutes (Methods; Fig. 1) and
caused an increase in mean renal perfusion pressure from about
40 mm Hg to values of about 190 mm Hg. We have shown
previously under very similar conditions that this relatively high
renal tonus does not affect the relative relaxant response to
PTHrP(1-34) and Ach in the isolated rabbit kidney [20]. In these
studies we checked that the relaxant responses to PTHrP and Ach
are strictly proportional to the preconstriction level for perfusion
pressures that ranged between 90 and 240 mm Hg.
(Rp)-cAMPS has been shown to directly inhibit cAMP-depen-
dent protein kinase [41, 42]. We employed this compound to
determine whether the activation of protein kinase A is directly
linked to the PTHrP(1-34)-induced vasorelaxation of the precon-
stricted isolated kidney (groups 2 and 5 in Fig. 1). We compared
PTHrP(1-34) with Fsk, a cAMP-dependent vasodilator [43] and
Ach, a NO-dependent, cAMP-independent renal vasodilator.
Figure 3 A and B show the changes in mean perfusion pressure
with time in the protocols used to compare the sensitivity of the
vasodilatory responses induced by iO M PTHrP(1-34), io M
Ach and 2.5 X iO M Fsk, to 10 M (Rp)-cAMPS. (Rp)-cAMPS
produced no measurable effects on the Nad-induced constriction
(Fig. 3 B, D). In absence of (Rp)-cAMPS, the maximal percent
decrease of the Nad-induced constriction produced by PTHrP(1-
34), Fsk and Ach were 35.2 2.2%, 55.1 2.5% and 28.8
5.0%, respectively (Fig. 4). The addition of (Rp)-cAMPS to the
recirculating perfusate significantly reduced, but did not com-
pletely prevent, the PTHrP(1-34)- and Fsk-induced vasorelaxation
by 57% and 53%, respectively. As expected, Ach-induced vasore-
laxation was not significantly affected by (Rp)-cAMPS.
Since we have previously shown that NO-synthase inhibition
markedly reduced PTHrP-induced vasorelaxation in the rabbit
kidney [20], we then asked whether or not the combined effect of
L-NAME, a specific NO-synthase inhibitor, and (Rp)-cAMPS
would be additive. The Nad-induced preconstriction was further
increased by io- M L-NAME with maximal percent increase of
16.2 4.4% in Figure 3C and by 20.4 5.3% in Figure 3D.
L-NAME markedly reduced, but again did not completely pre-
vent, the hPTHrP(1-34)- and Ach-induced relaxation, by 71% and
63%, respectively (Fig. 4). Conversely, the Fsk-induced relaxation
was not significantly affected by L-NAME. The combined effect of
(Rp)-cAMPS and L-NAME on PTHrP(1-34)-induced relaxation
was similar to the effect of each compound added separately.
Regarding Fsk- and Ach-induced relaxations, the combined effect
of the inhibitors was the same as the effect of either (Rp)-cAMPS
or L-NAME, respectively.
To further explore the involvement of the adenylyl cyclase
pathway, we compared the desensitization of PTHrP(1-34)-in-
duced vasorelaxation of the preconstricted isolated rabbit kidney
and PTHrP(1-34)-stimulated adenylyl cyclase pathway in isolated
rabbit renal microvessels. Figure 5 A to C show the changes in
mean perfusion pressure as a function of time in the protocols
used to characterize the desensitization of the vasorelaxant re-
sponses to PTHrP(1-34) in the isolated rabbit kidney, perfused at
constant flow in a single-pass circuit and preconstricted with 10
M Nad to 170 to 180 mm Hg. A first exposure to lOhI M
PTHrP(1-34) for five minutes dilated the renal vasculature by
inducing an 8.3 2.6% fall in perfusion pressure (Fig. 5A).
Exposure to 5 >< 1O M PTHrP(1-34) for one or five minutes
resulted in 42.6 1.4 and 36.2 3.5% reduction in perfusion
pressure, respectively (Fig. 5 B, C). The desensitizing effect of
these peptide infusions on the vasorelaxation produced by a
second one minute-S X i0 M infusion was measured after a
peptide-free interval of 10 minutes. The one or five minute
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Fig. 3. Mean tracings depicting the effect of iO M PTHrP(1-34), 1O' M
Ach and 2.5 X io M Fsk on perfusion pressure of recirculating isolated
rabbit kidneys perfused at constant flow and preconstricted with Nad, under
control conditions (A), after administration of JO M (Rp)-cAMPS (B),
JO M L-NAME (C) or both (D). The number of kidney preparations
performed in each group and protocols are illustrated in Figure I (groups
2, 4 to 6).
exposure to 5 X 10 M PTHrP(1-34) desensitized the vasodila-
tory response to the second infusion of peptide by 55.4 8.8 and
84.5 1.5%, respectively (Fig. 5D). Exposure to M
PTHrP(1-34) during one minute was able to significantly desen-
sitize, by 16.4 4.0%, the response to the second one-minute 5 X
10 M infusion of peptide.
Figure 6A shows the effect of treating homogenates derived
from microvessels purified from rabbit renal cortex for 10 min-
utes, with increasing concentrations of rPTH(1-34) on the PTH
concentration-response curve for adenylyl cyclase stimulation.
The EC5 value for adenylyl cyclase stimulation in control un-
treated vessels was 1.3 0.6 n, and the lowest concentration of
PTH producing a significant stimulation was 10'° M. However,
exposure to a concentration of PTH as low as lO M significantly
reduced the maximal effect observed with control-untreated ves-
sels by 24.7 2.3%. Exposures to 10 or i0 M PTH reduced
the maximal effect of the subsequent dose-response curve by
43.3 5.4 and 58.8 4.6%, respectively. On the other hand, the
EC50 value was not significantly affected by PTII-induced desen-
Fig. 4. Effect of io M 'Rp)-cAMPS (B), 10 4iwL-NAME (B) or both (
on the vasodilatoty responses to 10 M PTHrP(1-34), 1O MAch and 2.5 X
i0 M Fsk. Symbol () is control. Bars indicate the maximum percent
decrease of the Nad-induced constriction in recirculating isolated rabbit
kidneys perfused at constant flow. The number of kidney preparations
performed in each group and protocols are illustrated in Figure 1 (groups
2, 4 to 6). *p < 0.05.
sitization. As shown in Figure 6B, 10 minute treatments with
either i0 M PTHrP(1-34), i0 M rPTH(l-34) or 10 'M of the
whole hPTH(1-84) peptide, also desensitized both rPTH(1-34)-
and PTHrP(1-34)-responsive adenylyl cyclase of the isolated
microvessels. The desensitizing effects of both rPTH(1-34) and
PTHrP(1-34) pretreatments were markedly higher on PTHrP(1-
34)- than on rPTH(1-34)-responsive adenylyl cyclase, and treat-
ments with PTH fragments resulted in more substantial desensi-
tization of both rPTH(1-34)- and PTHrP(1-34)-responsive
adenylyl cyclase than treatments with PTHrP(1-34). To determine
whether protein kinase A is involved in the desensitization
process, crude microvessels were treated for 10 minutes with the
direct adenylyl cyclase stimulant Fsk [43], or the membrane
permeable cAMP analogue, dibutyryl-cAMP. Figure 6B shows
that neither maneuver blunted the responsiveness of microvessel
adenylyl cyclase to rPTH(1-34) or PTHrP(1-34). In contrast,
dibutyryl-cAMP had a paradoxical sensitizing, or potentiating
effect on rPTH(1-34) hut not on PTHrP(1-34)-responsive adenylyl
cyclase.
NO/NO -synthase-dependence of PTHrP-induced vasorelaxation in
the isolated rabbit kidney
The next series of studies was directed at the NO/NO-synthase
system. Specifically, we examined the effects of i0 M L-NAME,
of i0— M carboxy-PTIO (a NO scavenger), and of iO M MB (a
soluble guanylyl cyclase inhibitor) on PTHrP(I-34)-induced va-
sorelaxation (groups 1, 3, 7 and 8 in Fig. 1) in isolated recirculat-
ing perfused kidneys preconstricted with Nad. We compared
PTHrP to 2 X 10 vi Bk (a renal vasodilator which, in the
absence of the prostaglandin stimulatory pathway, acts solely
through the formation of NO [44, 451) and to 2.5 X iO vi Fsk.
In these series of experiments, the maximum vasoconstrictor
effects of L-NAME, MB and earboxy-PTIO, on the Nad-induced
preconstriction were 27.0 1.3%, 17.4 5.1% and 14.1 4.7%,
respectively (profiles of perfusion pressure changes not shown). In
the absence of inhibitor, the vasorelaxation produced by
PTHrP(1-34), Bk and Fsk were 36.3 2.3%, 17.6 3.2% and
55.6 1.4%, respectively (Fig. 7). The addition of L-NAME,
carboxy-PTIO or MB significantly reduced, hut did not completely
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Fig. 5. Mean tracings depicting the protocols used to display desensitization
of the vasorelaxant effect of a second one minute exposure to 5 x 108 M
PTHrP(1-34) (black rectangles) in the isolated rabbit kidneys exposed 10
minutes earlier with 10" M PTHrP(1-34) for five minutes (A, N = 5), 5 X10 M PTHrP(1-34) for one minute (B, N = 4) and 5 X j M
PTHrP(l-34) for five minutes (C, N = 4) (hatched rectangles). Rena!
preparations were perfused in single-pass circuit as described in the
Methods. (D) Relative reductions of Nad-induced constrictions (illustrat-
ed in A, B and C) produced by the first (hatched bars) and second (black
bars) PTHrP(1-34) administrations for the indicated durations and con-
centrations. The numbers shown within the pane! are the rate of desen-
sitization calculated by the ratio of the second one minute-5 X 10 vi
PTHrP(1-34) vasorelaxant responses to the unchallenged one minute-5 X
io M PTHrP(1-34) response taken as reference and represented in
pane! B. 8P < 0.05.
prevent, the PTHrP-induced vasorelaxation, by 57%, 27% and
34%, respectively, and abolished the Bk-induced vasorelaxation.
As expected, Fsk-induced vasorelaxation was not significantly
altered by these maneuvers.
Endothelium dependence of PTHrP-induced vasorelaxation in the
isolated rabbit kidney
The next experiments were performed to ask whether the
endothelium is required for the renal vasodilatory action of
PTHrP. Three different approaches were used to damage endo-
thelium of the preconstricted recirculating kidneys or to block
endothelium-derived NO (groups 9 to 11 in Fig. 1): (a) treatment
with an endothelial-targeted, complement fixing antiserum,
F8rAg-ab +cpmt; (b) treatment with CHAPS; and (c) treatment
with the anti-oxidant gossypol. Treatment of the isolated kidneys
with F8rAg-ab +cpmt, over the 10 first minutes of perfusion,
affected neither the baseline pressure during the equilibrating
period, nor the Nad-induced preconstriction (profiles of perfusion
pressure changes not shown). Initial treatment with CHAPS
resulted in a rapid and transient increase of basal perfusion
pressure but was without effect on the Nad-induced preconstric-
tion. The addition of gossypol increased Nad-induced vasocon-
striction by 8.9 1.7%.
As shown in Figure 8, none of these treatments was able to
significantly alter PTHrP- nor Fsk-induced vasorelaxation. In
contrast, all these treatments markedly reduced Bk-induced va-
sorelaxation by 69% (gossypol), 92% (CHAPS) and 53%
(F8rAg-ab + cpmt). L-NAME similarly affected PTHrP-induced
vasorelaxation, whether the kidneys were pretreated with
F8rAg-ab + cpmt or not (67% vs. 53% in groups 9 and 12,
respectively). In contrast, L-NAME further inhibited and thereby
virtually abolished the Bk-induced vasorelaxation that persisted
after pretreatment with F8rAg-ab + cpmt. Pretreatment with
F8rAg-ab + cpmt significantly reduced the vasoconstrictory effect
of L-NAME on the Nad-induced preconstriction from 21.3
2.7% (mean effect of L-NAME in groups 3, 4 and 6; N = 13) to
13.6 1.4% (in group 12).
Discussion
Immunohistological localization of PTHrP in human renal
vasculature
Immunostaining in glomerular epithelial and tubular cells of
the rat kidney has previously been reported [36]. Since PTHrP is
present in most other arterial systems [461, it appeared highly
likely that PTHrP is produced in the renal arterial tree, but this
had not been specifically documented. In the current study,
PTHrP was found to be present throughout the entire intrarenal
vascular network in humans, including the arterioles near the
glomerulus and the larger interlohular and arcuate arteries.
PTHrP was present not only within the media in smooth muscle
cells, but also within the intima in endothelial cells along the
entire intrarenal arterial tree. This latter finding is consistent with
the recent observation of Ishikawa et al [471 demonstrating the
constitutive production of PTHrP in cultured endothelial cells
obtained from bovine carotid artery. Further, in the present work
PTHrP was found in macula densa cells, in close contact with the
arteriolar wall. These findings suggest that PTHrP produced by
endothelial and macula densa cells may act, either directly or
indirectly, as a paracrine relaxing factor. The pattern of staining in
the media of the arterioles near the glomerulus invites the
speculation that PTHrP could be present not only in the smooth
muscle cells but also in the juxtaglomerular rcnin-secreting cells.
Given the previous observations demonstrating in physiological
concentrations that PTHrP causes a dramatic increase in the
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Fig. 6. Desensitization of rPTH(1-34)- and
PTHrP(1-34)-responsive adenylyl cyclase activities
of homogenate of microvessels isolated from
rabbit kidney cortex. The net increases over
basal adenylyl cyclase activity are shown. A.
Control untreated microvessels (none) have
been treated with either 10_11 M, i0 M or
i0 M rPTH(l-34) as indicated. Adenylyl
cyclase (ACase) activities were then measured
in response to increasing concentrations of
rPTH(1-34), as indicated. B. Microvessels have
been pretreated with various PTH/PTHrP-
derived peptides or unrelated agents, as
indicated. Adenylyl cyclase activities in response
to either io M rPTH(1-34) (LI) or i0 M
hPTHrP(1-34) (U) were then measured. The
numbers shown top of the bars represent the
percent decreases (desensitization) of adenylyl
cyclase activity calculated by the ratio of the
activity in pretreated microvessels to control
(CTL) untreated microvessels (*P < 0.05). The
results from both A and B are representative of
three separate experiments performed in
triplicate.
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release of renin from these cells [22], it seems likely that endog-
enous PTHrP could function as a factor that regulates locally the
release of renin. Since PTH is not synthetized in the vascular
network [361, it is possible that PTHrP induces its local renovas-
cular effects through PTH/PTHrP receptors present in renal
arterioles [8]. Thus, the ubiquitous distribution of PTHrP within
the juxtaglomerular apparatus, together with the previous obser-
vations demonstrating that PTHrP is produced in the glomerular
epithelial cells, strongly suggest that PTHrP may participate in the
regulation of glomerular blood flow. Direct demonstration of such
a role within the glomerulus and in adjacent vessels will require
further studies.
Role of cAMP-dependent signaling pathway in PTHrP-induced
vasodilation in the isolated rabbit kidney
A number of laboratories have shown that (Rp)-cAMPS is a
useful tool for distinguishing between protein kinase A-dependent
and protein kinase A-independent events, as for example PTH/
PTHrP-induced bone resorption [48] or PTHrP-induced aortic
relaxation [33]. The present results reveal that in the isolated
rabbit kidney preconstricted with Nad, (Rp)-cAMPS comparably
inhibited the vasorelaxation by PTHrP(1-34) and by Fsk, a direct
activator of adenylyl cyclase [43]. It seems unlikely that such
inhibitory effect of (Rp)-cAMPS is nonspecific or toxic, because
(Rp)-cAMPS did not affect Ach-induced vasorelaxation. How-
ever, neither PTHrP- nor Fsk-induced vasorelaxation was com-
pletely blocked by (Rp)-cAMPS. It is possible that the concentra-
tion of (Rp)-cAMPS used (i0— M) or incomplete membrane
permeability prevented complete inhibition of PTHrP- and Fsk-
induced vasorelaxation. Inasmuch as Fsk-induced vasorelaxation
is exclusively dependent upon the activation of protein kinase A,
and based on the similarity of the inhibitory effect of (Rp)-cAMPS
on Fsk- and PTHrP-induced vasorelaxation, an important conclu-
sion of the present study is that the activation of protein kinase A
signaling pathway plays a major role in the dilatory effect of
PTHrP in the renovascular system.
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Fig. 7. Effect of iO M L-NAME (), 1O M
carboxy-PTIO (), and iO- M MB ) on the
vasodilatoty responses to iO' M PTHrP(1-34),
2 x 1O M Bk and 2.5 X io— M Fsk. Symbol
(LI) is control. Bars indicate maximum percent
decrease of the Nad-induced constriction in
recirculating isolated rabbit kidneys perfused at
constant flow. The number of kidney
preparations performed in each group and
protocols are illustrated in Figure 1 (groups 1,
3, 7 and 8). 6P < 0.05.
Fig. 8. Effect of substances known to damage
vascular endothelium in the isolated kidney, on
the vasodilato,y responses to iO' M PTJ-frP(1-
34), 2 x IO6MBkand2.5 X lO7MFsk. The
number of kidney preparations performed in
each group and protocols are illustrated in
Figure 1 (groups 1, 9 to 12). The four left bars
represent the effect of 10—6 M gossypol (),
0.4% CHAPS () and 1:1000 diluted F8rAg-ab
+ 2% complement () and control (LI). The
two right bars represent the effect of iO— M
L-NAME () in kidney preparations pretreated
with F8rAg-ab + complement () as compared
to untreated kidneys. Bars indicate the
maximum percent decrease of the Nad-induced
constriction. *p < 0.05.
To further explore the cAMP-dependence, we asked whether
the desensitization of PTHrP(1-34)-induced vasorelaxation in the
isolated rabbit kidney would parallel desensitization of PTHrP(1-
34)-stimulated adenylyl cyclase in isolated rabbit renal microves-
sels. Such desensitization of PTHrP( 1-34)-induced renovascular
actions has not yet been reported. We found that renal vasore-
laxation responded within 10 minutes to short-term (1 to 5 mm)
treatment with PTHrP(1 -34) by a state of refractoriness to the
peptides. Desensitization was both time- and concentration-de-
pendent. Further, treatment with either PTHrP(i-34) or PTH
peptides desensitized both PTH- and PTHrP-responsive adenylyl
cyclase. The extent of tachyphylaxis to the vasorelaxing effect of
PTH/PTHrP closely paralleled the extent of desensitization of
PTH/PTHrP-responsive adenylyl cyclase in isolated rabbit renal
microvessels. Indeed, in renal microvessels, 10-minute treatment
with a concentration as low as l0 M or with io— M of PTH
reduced by 25 and 60%, respectively, the subsequent maximal
adenylyl cyclase response to i0 M of PTH. Accordingly, expo-
sure of the isolated perfused kidney to M PTHrP for five
minutes, or to 5 X 10 M for one minute, reduced by 16 and 55%,
respectively, the vasodilatory response to rechallenge with 5 X
10—8 M PTHrP, 10 minutes later. These results further identify
cAMP as a key signaling pathway of PTH/PTHrP-induced renal
vasodilation. We also found that treatment with PTH peptides
resulted in more substantial desensitization for both PTH- and
PTHrP-responsive adenylyl cyclase than treatment with PTHrP.
The significance of these findings is unclear. It is tempting to
speculate that protein kinase A activation may have mediated
desensitization by phosphorylating the PTH/PTHrP receptor.
However, Fsk, a direct adenylyl cyclase stimulant, or the mem-
brane permeable cAMP analogue, dibutyryl-cAMP, were unable
to inhibit subsequent adenylyl cyclase responsiveness to rPTH(1-
34) or PTHrP(1-34). Moreover, 10" at PTH, which had no
detectable effect on adenylyl cyclase activity, was still able to
desensitize maximal-stimulated enzyme activity. Together, these
results rather suggest that desensitization is a cAMP/protein
kinase A-independent process. The question as to whether the
phospholipase C/protein kinase C may play some role in the
PTHrP-mediated renal vasodilation, perhaps with regard to re-
ceptor desensitization, will need further investigations. The cur-
rent results also indicate that the decline of subsequent adenylyl
cyclase responsiveness was PTH/PTHrP-specific and therefore
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represented a homologous desensitization. This latter conclusion
is supported by recent findings from other laboratories on extra-
renal cultured vascular smooth muscle cells. Indeed, treatment of
aortic or mesenteric smooth muscle cells with Fsk or isoprotere-
nol in concentrations known to markedly increase cAMP did not
affect the subsequent cAMP response to PTH [27, 49].
Role of nitric oxide-dependent signaling pathway in PTHrP-
induced vasodilation in the isolated rabbit kidney
In a previous study [20], we showed that a component of the
vasorelaxant effect of PTHrP(1-34) in the isolated perfused rabbit
kidney was inhibited by L-NAME. Therefore, in addition to
cAMP, a substantial part of the renodilatory effect of PTHrP
might also be dependent upon the formation of NO. In the
present experiments, we extended these results by testing the
effect of maneuvers that interfere not only with the formation of
NO, but also with the action of NO. Carboxy-PTIO is an oxygen
donor for NO, which has been shown to react with NO, more than
10-fold faster than does molecular oxygen, and yields NO2 in a
stoechiometric manner in solutions, thus scavenging and inacti-
vating NO [50]. MB, which inhibits soluble guanylyl cyclase
probably by interaction with the heme group of the enzyme [51],
prevents the rise in cGMP and the action of NO on target smooth
muscle cells. Like L-NAME, carboxy-PTIO and MB caused an
increase of the vasoconstriction induced by Nad. Importantly,
these observations provide additional support for an involvement
of NO in the regulation of basal renal vascular tone [44].
L-NAME did not completely antagonize PTHrP- and Ach-in-
duced vasorelaxation, although it completely blocked Bk-induced
vasorelaxation in the absence of the cyclooxygenase-dependent
pathway. The present study also revealed that as with NO
formation, pharmacological blockade of NO action markedly
decreased PTHrP-induced vasorelaxation in the preconstricted
isolated perfused rabbit kidneys. As for L-NAME, these maneu-
vers did not completely antagonize PTHrP-induced vasorelax-
ation, although they completely blocked Bk-induced vasorelax-
ation. It seems improbable that the renovascular system contains
different PTHrP receptor subtypes mediating the stimulation of
different second messenger pathways since the combined effect of
near-maximal concentrations of L-NAME and (Rp)-cAMPS was
not additive. Additionally, L-NAME, carboxy-PTIO and MB had
higher inhibitory effect on Bk-induced vasorelaxation than on
PTHrP-induced vasorelaxation, whereas (Rp)-cAMPS compara-
bly inhibited Fsk- and PTHrP-induced renal vasorelaxation.
Therefore, NO-synthase/NO/guanylyl cyclase inhibition presum-
ably block PTHrP-induced vasorelaxation to a lesser degree than
protein kinase A inhibition. In support of this, both a marked
increase of cAMP and a small increase of cGMP were seen in
rabbit aortic strips during PTH-induced relaxation [24], indicating
that at least two mechanisms of cyclic nucleotidc-smooth muscle
relaxation coupling may be present in this system. These obser-
vations are consistent with the concept that cAMP is essential to
trigger the vasorelaxation in response to PTHrP and that the
activation of NO-synthase might be secondary to the activation of
adenylyl cyclase. At this point, it may be concluded that PTE-IrP-
mediated renal vasorelaxation presumably involves a complex
signal transduction pathway or combination of pathways involving
the formation of cAMP, NO and cGMP. This issue will he further
discussed below in the light of the results indicating that the
cAMP/NO-dependent PTHrP-induced renal vasodilation does
actually not require an intact endothelium.
Role of endothelium in PTHrP-induced vasodilation in the
isolated rabbit kidney
The role of the endothelium in PTHrP-induced vasorelaxation
has received relatively little attention. The observations described
above demonstrating NO-dependency of the renodilatory action
of PTHrP and the presence of PTHrP in endothelial cells strongly
suggest that an endothelium-mediated pathway may exist. Recent
studies show that the two constitutive NO-synthase isoforms
(endothelial or type III and neuronal or type I) are widely
distributed throughout the kidney of various species. Indeed,
constitutive NO-synthase is expressed not only in the endothelium
of the whole glomerulo-arteriolar network, but also in mesangium
and tubular cells including the macula densa [52—55]. Therefore
experiments were performed to explore whether the endothelium
was required for the renal vasodilatory action of PTHrP. Because
the endothelium cannot be readily removed from the microvas-
culature of intact kidney, we used three different approaches to
damage endothelium or block endothelium-derived NO. The first
approach is based on the fact that endothelial cells specifically
express factor Vill-related antigens and that complement reacts
with F8rAg-ab/antigen complexes, causing cell damage and lysis
[56]. This method has been shown to selectively eliminate endo-
thelium-dependent vasodilation from microperfused glomerular
afferent arteriole without damaging vascular smooth muscle cells
[56]. For the second approach, gossypol was used. Gossypol is
believed to inhibit the release and/or the production of endothe-
hum-derived NO in the isolated perfused rat kidney [44, 57]. For
the third approach, the detergent, CHAPS, was used, which has
also been used previously to remove endothelium in the isolated
perfused rat kidney [44, 58]. These treatments did not seem to
impair renal smooth muscle responsiveness, since they affected
neither the Nad-induced constriction, nor the Fsk-induced relax-
ation. None of the three endothelium-damaging techniques influ-
enced the renovasodilatory response to PTHrP. In contrast, all
three markedly decreased Bk-induced vasorelaxation. These find-
ings support the conclusion that PTHrP does not require an intact
endothelium to induce vasorelaxation in the kidney, despite the
involvement of a NO-dependent signaling pathway. If this is true,
then L-NAME should be able to reduce PTHrP-induced vasore-
laxation whether an intact endothelium is present or not. Indeed,
the inhibitory effect of L-NAME on PTHrP-induced vasorelax-
ation was not altered by pretreatment of the kidneys with the
endothelial antibody, F8rAg-ab + cpmt, although this treatment
abolished the Bk-induced vasorelaxation. It should be stressed
that the effects of the three different methods used to damage
endothelium were consistent, although the actual degree of
endothelium damage is difficult to determine.
Together, these results would simply imply that the L-NAME
sensitivity of PTHrP-induced vasorelaxation resulted from inhibi-
tion of an extraendothehial NO-synthase pool, namely smooth
muscle and/or tubular cell NO-synthase. There has been recent
evidence that the gene of inducible isoform of NO-synthase (type
II) is up-regulated by cAMP [59] and cGMP [601 in vascular
smooth muscle cells. Moreover, treatment of vascular smooth
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muscle cells with Fsk has been shown to induce GTP:cyclohydro-
lase mRNA expression, the regulatory enzyme of tetrahydrobiop-
term synthesis, the latter heing a required cofactor for NO-
synthase activity [61]. However, such mechanisms seem
improbable under the present experimental conditions since
up-regulation of inducible NO-synthase in smooth muscle cells
requires several hours. Moreover, it is noteworthy that phosphor-
ylation of purified constitutive NO-synthase from brain by protein
kinase A does not alter its activity [62]. Finally, constitutive
isoforms of NO-synthase (type I or III) have not been detected in
the muscle layer of the intrarenal vascular network [54]. At this
point it appears therefore unlikely that the sensitivity to L-NAME
of PTHrP-induced vasorelaxation resulted from inhibition of a
NO-synthase pool originating in the vascular smooth muscle cells.
Since strong presence of NO-synthase type I has been found in
macula densa as well as in the thick ascending limb [54], it is
tempting to speculate that the L-NAME sensitivity of PTHrP-
induced vasorelaxation resulted from inhibition of a tubular cell
NO-synthase. Obviously, further studies are necessary to claril
the extra-endothelial origin of the NO/cAMP-mediated vasodila-
tion induced by PTHrP in the kidney.
In summary, immunohistologic studies reveal that PTHrP is
present throughout the juxtaglomerular apparatus and along the
entire human renal vasculature, in both media and intima. Fur-
thermore, the present study indicates the direct involvement of
the cAMP/protein kinase A system and a contributory role of
NO/guanylyl cyclase system in the signal transduction system
mediating the vasodilatory action of PTHrP in the isolated
perfused rabbit kidney prteconstricted with Nad. Although
PTHrP is produced in renovascular endothelial cells, the in vitro
vasodilatory action of PTHrP in the kidney presumably does not
require an intact endothelium, which strongly suggests the in-
volvement of an extra-endothelial signal transduction pathway
implicating both cAMP/protein kinase A and NO/guanylyl cyclase
systems.
In extra-renal vascular beds PTHrP has been repeatedly dem-
onstrated to be vasorelaxant and to be present in both smooth
muscle and endothelial cells. Moreover, the major serum factor
responsible for the induction of PTHrP in vascular smooth
muscles appears to be angiotensin II. Further, PTHrP has repeat-
edly been shown to be induced by mechanical stretch in vascular
and extra-vascular smooth muscle cells (detailed references on
these issues are in [12]). The question as to whether angiotensin
II, a key factor in the regulation of renal hemodynamics, or
mechanical stretch (or increases in renal perfusion pressure) are
able to up-regulate PTHrP production within the renal gb-
merulo-vascular tree has not been addressed to date. Our previ-
ous findings demonstrated that PTHrP at physiological concen-
trations dilates the renal vascular tree under both in vivo and in
vitro conditions [7, 9, 20, 21, 63], increases renal blood flow [63],
single glomerulus flow [21] and glomerular filtration rate [63], and
causes a dramatic increase in the release of renin from juxtaglo-
merular cells [10]. From the present study it appears that PTHrP
is actually produced within the renal vascular tree and has a place
among the substances whose reno-vasodilatory actions implicate
NO generation, another key factor in the regulation of renal
hemodynamics [44, 51, 55, 57, 58]. Collectively, these findings
invite the speculation that PTHrP could play a significant modu-
latory role in maintaining renal blood flow. Clearly, much more
work needs to be done for the understanding of the normal
physiological roles of PTHrP in the renovascular system.
Acknowledgments
This work was supported by the French National Institute of Health
(ENSFRM) grant CRE 920203 and CJF 9409, the French Ministry of
Higher Education EA1314, and by the Department of Veterans Affairs,
West Haven, CT, USA. We thank Mrs. Elisabeth Friedmann, Jeanine
Krill and Suzanne Wendling for technical assistance, and Mrs. Sylvie
Rothhut and Danièle Kuhlwein for manuscript preparation.
Reprint requests to Dr. Jeun-Jocques Helwig, Loborutoire de Physiologic
('elluloire Rénale, Povillon Poincoré, Hospices Civils, B.? 426, F6709l
Strosbourg Cedex, Fronce.
Appendix
Abbreviations are: L-Arg, L-arginine-HCI; ATP or GTP, aden-
osine or guanosine 5'-triphosphate; Bk, bradykinin; cAMP or
eGMP, adenosine or guanosine 3'S'-eyclic monophosphate; ear-
boxy-PTIO, 2-(4-earboxyphenyl)-4,4,5,5-tetramethylimidazoline-
1-oxyl-3-oxide; CHAPS, 3-[(3-eholamidopropyl)-dimethylammo-
nio]-1 -propane-sulfonate; epmt, guinea pig complement;
dibutyryl-cAMP, N6,2'-O-dibutyryladenosine 3'S '-cyclic mono-
phosphate; F8rAg-ab, rabbit anti-human factor VIII-related anti-
gen; Fsk, forskolin; MB, methylene blue; rPTH(1-34), hPTH(1-
84) and hPTHrP(1-34), fragment 1-34 or 1-84 of rat or human
parathyroid hormone or PTH-related protein; Nad, noradrena-
line; L-NAME, N'°-nitro-L-arginine methyl ester; NO, nitric
oxide; (Rp)-eAMPS, (Rp)-adenosine cyclic 3',5'-phosphorothio-
ate.
References
1. MENARn J: Anthology of the renin angiotensin system—A 100 refer-
ence approach to angiotensin-It antagonists. J Hypertens 11(Suppl
3):53—S1l, 1993
2. SluoNsoN MS: Endothelins—Multifunctional renal peptides. Physiol
Rev 73:375—4t1, 1993
3. COnAN MG: Atrial natriuretic peptide. Kidney mt 37:1148—1160, 1990
4. RAOERMACUER J, KLANKE B, ScOuRER H-J, SToI.TE HF, FROLIcI-I JC:
Importance of NO/EDRF for glomerular and tubular function: Stud-
ies in the isolated perfused rat kidney. Kidney mt 41:1549—1559, 1992
5. RAtJ L, BAvus C: Glomerular actions nf nitric nxide. Kidney mt
48:20—32, 1995
6. Ntcicoi,s GA: Actions of parathyroid hormone in the cardiovascular
system. Blood Vessels 24:120, 1987
7. Musso MJ, BARTHELMEB5 M, IMBS JL, PLANTE M, BOLLAcK C,
IIELwlo JJ: The vasndilator action of parathyroid hormone fragments
on isolated perfused rat kidney. Nounyn-Schmiedehergs Arch Phanno-
col 340:246—251, 1989
8. NicKoLs GA, NicKoLs MA, HELwIG JJ: Binding of parathyroid
hormone and parathyrnid hnrmone-related protein tn vascular
smooth muscle of rabbit renal microvessels. Endocrinology 126:721—
727, 1990
9. Hvt,wio JJ, Musso MJ, Juims C, NicKoLs GA: Parathyroid hormone
and calcium: Interactions in the control of renin secretion in the
isolated, nonfiltering rat kidney. Endocrinology 129:1233—1242, 1991
10. SAussiNa C, Junus C, MASSFELDER T, Musso MJ, SIME0NI U,
HANNEDOUCHE T, HELwtG JJ: Stimulatory action of parathyroid
hormone on renin secretion in vitro: A study using isolated rat kidney,
isolated rabbit glomeruli and superfused dispersed rat juxtagbomeru-
bar cells. Clin Sci 84:11—19, 1993
11. 1 IALLORAN BP, NisseNsoN BA: Porothyroid Hormone-related Protein:
Normal Physiology ond Jts Role in Cancer. inca Raton, CRC Press,
Inc., 1992
12. PHILmsIcK WM, WY50LMER5KI JJ, GALBRAITH 5, HOLT E, ORLOFF JJ,
YANC KH, VA5AvAuA RC, Wcii EC, BltoAous AE, STEwART AF:
1602 Massfelder et al: PTH-related protein in renal vasculature
Defining the roles of parathyroid hormone-related protein in normal
physiology. Physiol Rev 76:127—173, 1996
13. M0K LLS, AJIWE F, MARTIN TJ, THOMPSON JC, COOPER CW:
Parathyroid hormone-related protein relaxes rat gastric smooth mus-
cle and shows cross-desensitization with parathyroid hormone. J Bone
Miner Res 4:433—439, 1989
14. BOTELLA A, REKIK M, DELVAUX M, DAVICCO MJ, BARLET JP,
FREXINOS J, BUENO L: Parathyroid hormone (PTH) and PTH-related
peptide induce relaxation of smooth muscle cells from guinea pig
ileum: Interaction with vasoactive intestinal peptide receptors. Endo-
crinology 135:2160—2167, 1994
15. YAMAMOTO M, HARM SC, GRASSER WA, THIEDE MA: Parathyroid
hormone-related protein in the rat urinary bladder—A smooth muscle
relaxant produced locally in response to mechanical stretch. Proc Nati
Acad Sci USA 89:5326—5330, 1992
16. SHEW RL, YEE JA, KLIEWER DB, KEFLEMARIAM YJ, MCNEILL DL:
Parathyroid hormone-related protein inhibits stimulated uterine con-
traction invitro. J Bone Miner Res 6:955—95 9, 1991
17. CRASS MF, SCARPACE PJ: Vasoactive properties of a parathyroid
hormone-related protein in the rat aorta. Peptides 14:179—183, 1993
18. NICKOLS GA, NAJ'A AD, NICKOLS MA, DIPETFE DJ, ASIMAKIS OK:
Hypotension and cardiac stimulation due to the parathyroid hormone-
related protein, humoral hypercalcemia of malignancy factor. Endo-
crinology 125:834—841, 1989
19. WINQUIST RJ, BASKIN EP, VLASUK GP: Synthetic tumor derived
human hypercalcemic factor exhibits parathyroid hormone-like Va-
sorelaxation in renal arteries. Biochem Biophys Res Commun 149:227—
232, 1987
20. SIMEONI U, MASSFELDER T, SAUSSINE C, JUDES C, GEISERT J, HELWIG
JJ: Involvement of nitric oxide in the vasodilatory response to
parathyroid hormone-related peptide in the isolated rabbit kidney.
Clin Sci 86:245—249, 1994
21. ENDLICH K, MASSFELDER T, HELWIG JJ, STEINHAUSEN M: Vascular
effects of parathyroid hormone (PTH) and PTH-related protein in the
split hydronephrotic rat kidney. JPhysiol (London) 483:481—490, 1995
22. SAUSSINE C, MASSFELDER T, PARNIN F, JUDES C, SIMEONI U, HELWIG
JJ: Renin stimulating properties of parathyroid hormone-related
peptide in the isolated perfused rat kidney. Kidney mt 44:764—773,
1993
23. NICKOLS GA: Increased cyclic AMP in cultured vascular smooth
muscle cells and relaxation of aortic strips by parathyroid hormone.
EurJPharmacol 116:137—144, 1985
24. NICKOLS GA, CLINE WH JR: Parathyroid hormone-induced changes
in cyclic nucleotide levels during relaxation of the rat aorta. Life Sci
40:2351—2359, 1987
25. BERGMANN C, SCHOEFFTER P, STOCLET JC, GAIRARD A: Effect of
parathyroid hormone and antagonist on aortic cAMP levels. Can
J Physiol Phar,nacol 65:2349—2353, 1987
26. NICKOLS GA, METZ MA, CLINE WH JR: Endothelium-independent
linkage of parathyroid hormone receptors of rat vascular tissue with
increased adenosine 3',5'- monophosphate and relaxation of vascular
smooth muscle. Endocrinology 119:349—356, 1986
27. HANSON AS, LINAS SL: Parathyroid hormone/adenylate cyclase cou-
pling in vascular smooth muscle cells. Hypertension 23:468—475, 1994
28. PANG PKT, YANG McM, TENNER TE JR, KENNY AD, COOPER CW:
Cyclic AMP and the vascular action of parathyroid hormone. Can
J Physiol Phar,nacol 64:1543—1547, 1986
29. Musso MJ, PLANTE M, JunEs C, BARTHELMEBS M, HELWIG JJ: Renal
vasodilation and microvessel adenylate cyclase stimulation by syn-
thetic parathyroid hormone-like protein fragments. Eur J Pharmacol
174: 139—151, 1989
30. HELWIG JJ, SCHLEIFFER R, JUDES C, GAIRARD A: Distribution of
parathyroid hormone-sensitive adenylate cyclase in isolated rabbit
renal cortex microvessels and glomeruli. Life Sci 35:2649—2657, 1984
31. Wu SX, PIROLA CJ, GREEN J, YAMAGUCHI DT, OINo K, JUEPPNER
H, FORRESTER JS, FAGIN JA, CLEMENS TL: Effects of N-terminal,
midregion, C-terminal parathyroid hormone-related peptides on
adenosine 3',5'-monophosphate and cytoplasmic free calcium in rat
aortic smooth muscle cells and UMR-106 osteoblast-like cells. Endo-
crinology 133:2437—2444, 1993
32. OKANO K, Wu SX, HUANG XP, PIROLA CJ, JUPPNLR H, ABOUSAMRA
AB, SEGRE GV, IWASAKI K, FAGIN JA, CLEMENS TL: Parathyroid
hormone (PTH)/PTH-related protein (PTHrP) receptor and its mes-
senger ribonucleic acid in rat aortic vascular smooth muscle cells and
UMR osteoblast-like cells: Cell-specific regulation by angiotensin-Il
and PTHrP. Endocrinology 135:1093—1099, 1994
33. ISHIKAWA M, OUCHIY, HAN SZ, AKISHITA M, KOZAKI K, TOBA K,
NAMIKI A, YAMAGUCHI T, ORIM0 H: Parathyroid hormone-related
protein reduces cytosolic free Ca2 level and tension in rat aortic
smooth muscle. Eur J Pharmacol 269:311—3 17, 1994
34. SCHULZE MR, MUGGE A, HARMS HM, CREMER J, FROMBACH R,
LICHTLEN PR: Human parathyroid hormone dilates both pig coronary
and human inferior epigastric arteries by a cyclic AMP-dependent
pathway. Artery 20:147—162, 1993
35. Soi NE, DEE KE, INSOGNA KL, BURTIS WJ, MATOVCIK LM, Wu
TL, MILSTONE LM, BROADUS AE, PHILBRICK WM, STEWART AF:
Parathyroid hormone-related protein—Evidence for secretion of a
novel mid-region fragment by 3 different cell types. J Biol Chem
267:18236—18243, 1992
36. S0IFER NE, VANWHY SK, GANZ MB, KASHGARIAN M, SIEGEL NJ,
STEWART AF: Expression of parathyroid hormone-related protein in
the rat glomerulus and tubule during recovery from renal ischemia.
J Clin Invest 92:2850—2857, 1993
37. BURTIS WJ, BRADY TG, ORLOFF JJ, ERSBAK JB, WARRELL RP, OLSON
BR, WU TL, MITNICK ME, BROADUS AE, STEWART AF: Immuno-
chemical characterization of circulating parathyroid hormone related
protein in patients with hunioral hypercalcemia of cancer. N EngI
JMed 322:1106—1112, 1990
38. YANG KR, DEPAPP AE, SOIFER NE, DREYER BE, Wv TL, PORTER SE,
BELLANTONI M, BURTIS WJ, INSOGNA KL, BROADUS AE, PHILBRICK
WM, STEWART AF: Parathyroid hormone-related protein: Evidence
for isoform- and tissue-specific posttranslational processing. Biochem-
istly 33:7460—7469, 1994
39. WIESEL PH, SEMMEKROT BA, GRIGORAS 0, HEUMANN C, GUIGNARD
JP: Pharmacological doses of atrial natriuretic peptide ameliorate the
acute renal dysfunction induced by systemic hypoxemia. J Pharmacol
Exp Ther 254:971—975, 1990
40. HELWIG JJ, JUDES C, BOLLACK C, MANDEL P: Isolation and charac-
terization of a microvascular fraction from rabbit kidney cortex. Renal
Physiol 7:146—155, 1984
41. PEREIRA ME, SEGALOFF DL, ASCOLI M, ECKSTEIN F: Inhibition of
choriogonadotropin-activated steroidogenesis in cultured Leydig tu-
mor cells by the Rp diastereoisomer of adenosine 3',S'-cyclic phos-
phorothioate. J Biol Chem 262:6093—6100, 1987
42. ROTHERMEL JD, JASTORFF B, BOTELHO LHP: Inhibition of glucagon-
induced glycogenolysis in isolated rat hepatocytes by the Rp diaste-
reoisomer of adenosine cyclic 3',5'-phosphorothioate. J Biol Chem
259:8151—8155, 1984
43. SEAMON KB: Activation of hormone-sensitive adenylate cyclasc by
forskolin. Drug Develop Res 6:181—192, 1985
44. KING AJ, BRENNER BM: Endothelium-derived vasoactive factors and
the renal vasculature. Am J Physiol 260:R653—R662, 1991
45. KOLLER A, RODENBURG JM, KALEY G: Effects of Hoe-140, ramiprilat
on arteriolar tone and dilation to bradykinin in skeletal muscle of rats.
Am J Physiol 37:H1628—H1633, 1995
46. OGINO K, BURKHOFF D, BILEZIKIAN JP: The hemodynamic basis for
the cardiac effects of parathyroid hormone (PTH) and PTH-related
protein. Endocrinology 136:3024—3030, 1995
47. ISHIKAWA M, OUCH! Y, AKISHITA M, KOZAKI K, TOBA K, NAMIKI A,
YAMAGUCHI T, ORIM0 H: Immunocytochemical detection of parathy-
roid hormone-related protein in vascular endothelial cells. Biochem
Biophys Res Comm 199:547—551, 1994
48. KAi H, SuGIM0T0 T, FUKASE M, CHIHARA K: Role of dual signal
transduction systems in the stimulation of bone resorption by para-
thyroid hormone-related peptide—The direct involvement of cAMP-
dependent protein kinase. Horm Metab Res 25:421—424, 1993
49. NYBY MD, HIN0 T, BERGER ME, ORMSBY BL, GOLUIi MS, BRICKMAN
AS: Desensitization of vascular tissue to parathyroid hormone and
parathyroid hormone-related protein. Endocrinology 136:2497—2504,
1995
50. YOSHIDA K, AKAIKE T, Do! T, SATO K, IJIRI 5, SUGA M, ANDO M,
MAEDA H: Pronounced enhancement of NO-dependent antimicrobial
action by an NO-oxidizing agent, Imidazolineoxyl N-oxide. Infect
Immun 61:3552—3555, 1993
Massfelder et al: PTH-related protein in renal vasculature 1603
51. MONCADA S, PALMER RMJ, HIGGS EA: Nitric oxide—Physiology,
pathophysiology, and pharmacology. Pharmacol Rev 43:109—142, 1991
52. MUNDEL P, BACHMANN S, BADER M, FISCHER A, KUMMER W, MAYER
B, KRIz W: Expression of nitric oxide synthase in kidney macula densa
cells. Kidney mt 42:1017—1019, 1992
53. WILCOX CS, WELCH WJ, MURAD F, GROSS SS, TAYLOR G, LEVI R,
SCHMIDT HHHW: Nitric oxide synthase in macula densa regulates
glomerular capillary pressure. Proc Nati Acad Sci USA 89:11993—
11997, 1992
54. BACHMANN 5, BOSSE HM, MUNDEL P: Topography of nitric oxide
synthesis by localizing cOnstitutive NO synthases in mammalian
kidney. Am J Physiol 37:F885—F898, 1995
55. TAMAKI T, ABE Y: Control of renal circulation—With special reference
on nitric oxide. Asia Pacific J Pharmacol 9:97—112, 1994
56. JUNCOS LA, ITO 5, CARRETERO OA, GARVIN EL: Removal of
endothelium-dependent relaxation by antibody and complement in
afferent arterioles. Hypertension 23:154—159, 1994
57. RADERMACHER J, FORSTERMANN U, FROLICH JC: Endothelium-de-
rived relaxing factor influences renal vascular resistance. Am J Physiol
259:F9—F17, 1990
58. BHARDWAJ R, MOORE PK: The effect of arginine and nitric oxide on
resistance blood vessels of the perfused rat kidney. Br J Pharmacol
97:739—744, 1989
59. IMAI T, HIRATA Y, KANNO K, MARUMO F: Induction of nitric oxide
synthase by cyclic AMP in rat vascular smooth muscle cells. J Clin
Invest 93:543—549, 1994
60. INOUE T, FUKUO K, NAKAHASHI T, I-IATA S, MORIMOT0 5, OGII-IARA
T: cGMP upregulates nitric oxide synthase expression in vascular
smooth muscle cells. Hypertension 25:711—714, 1995
61. SCOTTBURDEN T, ELIZONDO E, GE T, BOULANGER CM, VANHOUTrE
PM: Simultaneous activation of adenylyl cyclase and protein kinase C
induces production of nitric oxide by vascular smooth muscle cells.
Mol Pharmacol 46:274—282, 1994
62. HIROKAWA K, OSHAUGHNESSY K, MOORE K, RAMRAKHA P, WILKINS
MR: Induction of nitric oxide synthase in cultured vascular smooth
muscle cells: The role of cyclic AMP. Br J Pharmacol 112:396—402,
1994
63. MASSFELDER T, PAREKH N, ENDLICH K, SAUSSINE C, STEINHAUSEN M,
HELWIG JJ: Effect of intrarenally infused parathyroid hormone-
related protein on renal blood flow and glomerular filtration rate in
anesthetised rat. Br J Phar,nacol (in press)
